Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals is a biopharmaceutical company serving patients and families affected by rare diseases through the discovery, development and commercialization of therapies. The company has developed and commercialized two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody positive. In addition, the company has two enzyme replacement therapies for metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency.
  • TickerALXN
  • ISINUS0153511094
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
ALXN Alexion Pharmac... (Health Care)

ALEXION PHARMA sees a downgrade to Neutral on account of less fundamen...

The independent financial analyst theScreener just lowered the general evaluation of ALEXION PHARMA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date March 26, 2021, the closing price was USD 154.88 and its target price was estimated at USD 121.67.

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
Dave Nicoski
  • Dave Nicoski
ALXN Alexion Pharmac... (Health Care)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength. For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.

Dave Nicoski
  • Dave Nicoski
ALXN Alexion Pharmac... (Health Care)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength. For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.

 PRESS RELEASE
ALXN Alexion Pharmac... (Health Care)

SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention o...

BOSTON--(BUSINESS WIRE)-- (NASDAQ:ALXN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the extension of the current marketing authorization of SOLIRIS® (eculizumab) to include the prevention of relapse in patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica. “We are pleased that the Japanese health authorities have approved SOLIRIS as a new treatment for patients suffering from this complex and unpredictable disease,” said John Orloff, M.D., Executive Vice President and...

 PRESS RELEASE
ALXN Alexion Pharmac... (Health Care)

Alexion to Present at the Bank of America Merrill Lynch 2018 Health Ca...

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Wednesday, May 16, 2018 at 2:20 p.m., PDT. An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.alexion.com. An archived version of the remarks will also be available through the Company’s website for a limited time following the conference. [ALXN-G] View sour...

 PRESS RELEASE
ALXN Alexion Pharmac... (Health Care)

Alexion Reports First Quarter 2018 Results and Positive Topline Data f...

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the first quarter of 2018. Total revenues in the first quarter were $930.9 million, a 7 percent increase compared to the same period in 2017. First quarter 2017 revenues included a benefit of $49.2 million due to both the recognition of deferred revenue and timing of orders from certain non-U.S. markets that access Alexion's products through a tender process. The benefit of foreign currency on total revenues year-over...

 PRESS RELEASE
ALXN Alexion Pharmac... (Health Care)

Alexion Provides Statement on Superior Court of Justice (STJ) Decision...

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Recent media reports have incorrectly stated that the Brazilian Superior Court of Justice has granted a compulsory license of Soliris® (eculizumab). Alexion would like to clarify that no compulsory license of Soliris® was requested or granted in Brazil. The recent decision by the court refers to a different legal matter with the Brazilian Patent Office related to a Soliris® mailbox patent that expired in 2015. Alexion is evaluating the full decision by the court in this patent case before exploring ...

 PRESS RELEASE
ALXN Alexion Pharmac... (Health Care)

Alexion to Report First Quarter 2018 Results on Thursday, April 26, 20...

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2018 on Thursday, April 26, 2018 before the US financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio webcast on Thursday, April 26, 2018, at 10:00 a.m. Eastern Time (ET). To participate in this conference call, dial 888-394-8218 (USA) or 323-701-0225 (International),...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
Valens Research
  • Valens Research
ALXN Alexion Pharmac... (Health Care)

ALXN - Embedded Expectations Analysis - 2021 01 11

Alexion Pharmaceuticals, Inc. (ALXN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 10.5x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management appears concerned about ULTOMIRIS's markets, the pipeline's potential, and Andexxa's value proposition Specifically, management may lack confidence in their ability to maintain their leadership in the Paroxysmal Nocturnal Hemoglobinuria (PNH) market and make ULTOMIRIS the leader in the atypical Hemolytic Uremic Syndrome (aHUS) market. In addition, they may be e...

ALXN Alexion Pharmac... (Health Care)

ALEXION PHARMA sees a downgrade to Neutral on account of less fundamen...

The independent financial analyst theScreener just lowered the general evaluation of ALEXION PHARMA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date March 26, 2021, the closing price was USD 154.88 and its target price was estimated at USD 121.67.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch